Vindesine in the treatment of malignant mesothelioma: A phase II study

D. Kelsen, R. Gralla, E. Cheng, N. Martini

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)821-822
Number of pages2
JournalCancer Treatment Reports
Volume67
Issue number9
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vindesine in the treatment of malignant mesothelioma: A phase II study'. Together they form a unique fingerprint.

  • Cite this

    Kelsen, D., Gralla, R., Cheng, E., & Martini, N. (1983). Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treatment Reports, 67(9), 821-822.